View clinical trials related to Lymphoma Cns.
Filter by:This research is being done to test the safety and effectiveness of axicabtagene ciloleucel (axi-cel), an anti-CD19 directed chimeric antigen receptor (CAR) T-cell therapy in treating relapsed/refractory central nervous system (CNS) lymphoma, systemic lymphoma with concurrent CNS lymphoma, or systemic lymphoma with a history of treated CNS lymphoma, and to better understand what causes neurological toxicity following treatment with axi-cel. The names of the study drug(s) involved in this study are: - axicabtagene ciloleucel (axi-cel) - ludarabine will be given with axicel to help axicel work more effectively - cyclophosphamide will be given with axicel to help axicel work more effectively